When selecting between topical roflumilast and topical corticosteroids for seborrheic dermatitis in an area with a high actinic keratosis burden, could choosing a PDE4 inhibitor like roflumilast theoretically deliver a beneficial anti-neoplastic field effect while simultaneously clearing the patient's seborrheic dermatitis?

1 Answers

Mednet Member

Dermatology · UCLA

To my knowledge, there's no published trial data showing topical roflumilast reduces AK counts, reduces SCC incidence, or produces a measurable field effect. I love coming up with hypotheses, but remember, based on current clinical evidence, this hypothesis may be a side benefit story rather than a ...